Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Zealand Pharma begins dosing in Phase III trial for CHI

Givosiran is an investigational RNAi therapeutic formulated for subcutaneous administration. Credit: qimono via Pixabay.



  • Zealand Pharma begins dosing in Phase III trial for CHI

Go Top